2000
DOI: 10.1006/exnr.2000.7411
|View full text |Cite
|
Sign up to set email alerts
|

Implantation of Bioactive Growth Factor-Secreting Rods Enhances Fetal Dopaminergic Graft Survival, Outgrowth Density, and Functional Recovery in a Rat Model of Parkinson's Disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
22
0

Year Published

2002
2002
2024
2024

Publication Types

Select...
10

Relationship

3
7

Authors

Journals

citations
Cited by 54 publications
(22 citation statements)
references
References 61 publications
0
22
0
Order By: Relevance
“…GDNF also improved the graft-derived reinnervated volume of adult host striatum, but did not change the pattern of dopaminergic reinnervation, i.e. from diffuse and sparse to dense and patchy (Törnqvist et al, 2000). However, GDNF treatment of mature dopamine grafts did not affect survival and outgrowth from grafted dopamine neurons (Johansson et al, 1995;Winkler et al, 2006), but enhanced nerve fiber formation within the grafts, a phenomenon also found using other factors .…”
Section: Introductionmentioning
confidence: 65%
“…GDNF also improved the graft-derived reinnervated volume of adult host striatum, but did not change the pattern of dopaminergic reinnervation, i.e. from diffuse and sparse to dense and patchy (Törnqvist et al, 2000). However, GDNF treatment of mature dopamine grafts did not affect survival and outgrowth from grafted dopamine neurons (Johansson et al, 1995;Winkler et al, 2006), but enhanced nerve fiber formation within the grafts, a phenomenon also found using other factors .…”
Section: Introductionmentioning
confidence: 65%
“…27,28 The development and clinical application of carmustine-loaded polymers have demonstrated the effectiveness of local chemotherapy against malignant gliomas in experimental models 12 and ongoing clinical trials. 13,14,28 The use of polymer matrices to deliver pharmacotherapy interstitially to the CNS has also been accomplished in experimental models of neurodegenerative disorders, 29 brain edema, 30 and chronic posthemorrhagic vasospasm. 6,31 We have previously described the release kinetics of the DETA/NO-EVAc polymer used in this investigation and demonstrated the favorable pharmacokinetics of this polymer construct for intracranial delivery of exogenous NO.…”
Section: Discussionmentioning
confidence: 99%
“…Indeed, the emerging field of tissue engineering requires accurate delivery of bioactive and/or therapeutic molecules to a specific location. To this end, the use of polymeric delivery vehicles in the form of micro-or nano-spheres/particles to encapsulate the active molecules and maintain a sustained localised delivery to the target site is attractive [20][21][22].…”
Section: Introductionmentioning
confidence: 99%